Product characteristics
| . | Fresh . | Cryopreserved . | . | ||
|---|---|---|---|---|---|
| Domestic . | International . | Domestic . | International . | ||
| Product characteristics . | Median (range) . | Median (range) . | Median (range) . | Median (range) . | P . |
| Overall age of product (h) | 21 (2-71) | 36 (15-65) | 24 (4-61) | 58 (3 −84) | <.001 |
| Final TNC dose (108 cells/kg)* | 8 (3.8-17.4) | 7.9 (2.4-14.8) | 8 (3.6-16) | 6.9 (2.3-13.8) | .01 |
| Final TNC viability by 7AAD (%)* | 96.2 (37.4-99.4) | 92.9 (77.2-98.9) | 92.6 (71-99.3) | 86.5 (67.8-95.7) | <.001 |
| Final CD34 dose (106 cells/kg)* | 8.1 (1.5-32.5) | 7 (0.8-22.3) | 7.8 (2.1-26.1) | 7.5 (1.4-27.2) | .052 |
| Final CD34 viability by 7AAD (%)* | 98.6 (74.8-99.8) | 98.9 (49.7-99.9) | 98.2 (62.2-99.5) | 98 (92.2-99.7) | .19 |
| Post-thaw TNC viability by TB (%) | N/A | N/A | 80 (62-94) | 79 (67-96) | N/A |
| Age of product breakdown (h) | |||||
| Transit time, median (range) | 9.1 (0.9, 68.2) | 33.8 (13.9, 58.8) | 12.2 (1.5, 58.4) | 43.7 (22.2, 82) | <.0001 |
| Holding time, median (range) | 9.7 (0.4, 27) | 1.2 (0.2, 21.5) | 11.2 (0.4, 22.7) | 12.5 (0.3, 31.2) | <.0001 |
| Processing time, median (range) | 1.0 (1.0, 3.6) | 1.0 (1.0, 2.8) | 1.8 (1.0, 2.5) | 1.8 (1.0, 2) | <.0001 |
| . | Fresh . | Cryopreserved . | . | ||
|---|---|---|---|---|---|
| Domestic . | International . | Domestic . | International . | ||
| Product characteristics . | Median (range) . | Median (range) . | Median (range) . | Median (range) . | P . |
| Overall age of product (h) | 21 (2-71) | 36 (15-65) | 24 (4-61) | 58 (3 −84) | <.001 |
| Final TNC dose (108 cells/kg)* | 8 (3.8-17.4) | 7.9 (2.4-14.8) | 8 (3.6-16) | 6.9 (2.3-13.8) | .01 |
| Final TNC viability by 7AAD (%)* | 96.2 (37.4-99.4) | 92.9 (77.2-98.9) | 92.6 (71-99.3) | 86.5 (67.8-95.7) | <.001 |
| Final CD34 dose (106 cells/kg)* | 8.1 (1.5-32.5) | 7 (0.8-22.3) | 7.8 (2.1-26.1) | 7.5 (1.4-27.2) | .052 |
| Final CD34 viability by 7AAD (%)* | 98.6 (74.8-99.8) | 98.9 (49.7-99.9) | 98.2 (62.2-99.5) | 98 (92.2-99.7) | .19 |
| Post-thaw TNC viability by TB (%) | N/A | N/A | 80 (62-94) | 79 (67-96) | N/A |
| Age of product breakdown (h) | |||||
| Transit time, median (range) | 9.1 (0.9, 68.2) | 33.8 (13.9, 58.8) | 12.2 (1.5, 58.4) | 43.7 (22.2, 82) | <.0001 |
| Holding time, median (range) | 9.7 (0.4, 27) | 1.2 (0.2, 21.5) | 11.2 (0.4, 22.7) | 12.5 (0.3, 31.2) | <.0001 |
| Processing time, median (range) | 1.0 (1.0, 3.6) | 1.0 (1.0, 2.8) | 1.8 (1.0, 2.5) | 1.8 (1.0, 2) | <.0001 |
N/A, not applicable.
Final TNC and CD34 dose and viability are measured immediately after product processing (performed at our institution) and, in the case of fresh products, immediately prior to delivery to the patient floor for infusion. For cryopreserved products, these are measured after product processing immediately prior to cryopreservation. Upon thaw of cryopreserved products, TNC viability is measured by trypan blue (TB) prior to delivery to patient floor for infusion.